Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Yu-Jui Yvonne Wan"'
Autor:
Tahereh Setayesh, Ying Hu, Farzam Vaziri, Xin Chen, Jinping Lai, Dongguang Wei, Yu-Jui Yvonne Wan
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 14, Iss 1, Pp 292-303 (2024)
This study examines inhibiting galectin 1 (Gal1) as a treatment option for hepatocellular carcinoma (HCC). Gal1 has immunosuppressive and cancer-promoting roles. Our data showed that Gal1 was highly expressed in human and mouse HCC. The levels of Gal
Externí odkaz:
https://doaj.org/article/1b0e0a750c404ac3a677eaca20eec4f9
Publikováno v:
Liver Research, Vol 7, Iss 4, Pp 296-303 (2023)
Over 20% of mortality during acute liver failure is associated with the development of hepatic encephalopathy (HE). Thus, HE is a complication of acute liver failure with a broad spectrum of neuropsychiatric abnormalities ranging from subclinical alt
Externí odkaz:
https://doaj.org/article/27f129de6d274fef91120034bec2282f
Publikováno v:
Advanced Science, Vol 11, Iss 14, Pp n/a-n/a (2024)
Abstract This study investigates Bacillus Calmette‐Guérin (BCG) as a potential treatment for hepatocellular carcinoma (HCC), a condition often associated with unfavorable treatment outcomes. Exploiting BCG's recognized immune‐boosting properties
Externí odkaz:
https://doaj.org/article/c0c720e7eecc4b21b6d4b8852496ea78
Autor:
Ryan Mifflin, Jung Eun Park, Mikang Lee, Prasant Kumar Jena, Yu-Jui Yvonne Wan, Hazel A. Barton, Mirjavid Aghayev, Takhar Kasumov, Li Lin, Xinwen Wang, Robert Novak, Feng Li, He Huang, Leah P. Shriver, Yoon-Kwang Lee
Publikováno v:
Journal of Lipid Research, Vol 64, Iss 12, Pp 100469- (2023)
Deletion of the nuclear hormone receptor small heterodimer partner (Shp) ameliorates the development of obesity and nonalcoholic steatohepatitis (NASH) in mice. Liver-specific SHP plays a significant role in this amelioration. The gut microbiota has
Externí odkaz:
https://doaj.org/article/31e7db3968334b6faf41f7140714318f
Publikováno v:
Liver Research, Vol 7, Iss 2, Pp 116-123 (2023)
Metabolic diseases have overtaken infectious diseases as the most serious public health issue and economic burden in most countries. Moreover, metabolic diseases increase the risk of having infectious diseases. The treatment of metabolic disease may
Externí odkaz:
https://doaj.org/article/b69add80b10b46209e416c315a9748d0
Autor:
Guiyan Yang, Prasant K. Jena, Ying Hu, Lili Sheng, Shin-Yu Chen, Carolyn M. Slupsky, Ryan Davis, Clifford G. Tepper, Yu-Jui Yvonne Wan
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-19 (2023)
Abstract Background Aging and diet are risks for metabolic diseases. Bile acid receptor farnesoid X receptor (FXR) knockout (KO) mice develop metabolic liver diseases that progress into cancer as they age, which is accelerated by Western diet (WD) in
Externí odkaz:
https://doaj.org/article/892d84c93f6c443d9942c868c6d8197d
Publikováno v:
Nutrients, Vol 15, Iss 15, p 3406 (2023)
Western diet (WD) intake, aging, and inactivation of farnesoid X receptor (FXR) are risk factors for metabolic and chronic inflammation-related health issues ranging from metabolic dysfunction-associated steatotic liver disease (MASLD) to dementia. T
Externí odkaz:
https://doaj.org/article/3f4b7dd21e034a4eafcd97a155a3f48b
Publikováno v:
Liver Research, Vol 4, Iss 4, Pp 191-198 (2020)
The incidence of hepatocellular carcinoma (HCC) has been increasing for decades. This disease has now risen to become the sixth most common malignancy overall, while ranking as the third most frequent cause of cancer mortality. While several surgical
Externí odkaz:
https://doaj.org/article/d7430810aaf94bd38b0c2dbf7c66db0a
Publikováno v:
Liver Research, Vol 4, Iss 4, Pp 173-179 (2020)
Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different types of cancer. Among the 11 Gals identif
Externí odkaz:
https://doaj.org/article/28f32c32de6141c29b1739dab4dd7c56
Publikováno v:
Liver Research, Vol 4, Iss 4, Pp 168-172 (2020)
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be control
Externí odkaz:
https://doaj.org/article/a9f16afa5be147538113171dd52a2c80